Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06656494 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 18 → 22 locationsv8
  2. Trial sites expanded: 15 → 18 locationsv7
  3. Study sites: 14 to 15v6
  4. Enrollment target: 206 to 266 Study sites: 6 to 14 · Eligibility criteria shortened, about 3 wordsv5 Show 2 more changesShow less
    • Study sites: 6 to 14
    • Eligibility criteria shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  5. Enrollment target: 102 to 206 Primary endpoints: 5 to 6 · Study sites: 2 to 6 · Eligibility criteria shortened, about 188 words · 2 morev4 Show 5 more changesShow less
    • Primary endpoints: 5 to 6
    • Study sites: 2 to 6
    • Eligibility criteria shortened, about 188 words
    • Secondary endpoints: 13 to 20
    • Study title shortened, about 9 words

    See this version in full on ClinicalTrials.gov ↗

Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 1 to 2 Start date: Dec 17, 2024 to Dec 18, 2024v3 Show 1 more changeShow less
    • Start date: Dec 17, 2024 to Dec 18, 2024
  2. Trial status: Not Yet Recruiting to Recruiting Enrollment target: 90 to 102 · Study sites: 0 to 1 · Start date changed from estimate of Nov 2024 to Dec 17, 2024 · 1 morev2 Show 4 more changesShow less
    • Enrollment target: 90 to 102
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 2024 to Dec 17, 2024
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.
Trial Details
NCT Number NCT06656494
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
Enrollment 266 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov